Photo detail

Paul Laikind is the CEO of ViaCyte, a San Diego company flying high with a recent $80 million Series D round. Photo courtesy of ViaCyte

Stories this photo appears in:

ViaCyte Gets $80M Series D For Pursuit of Diabetes Cure

ViaCyte recently hauled in an $80 million Series D round to advance therapies that the company called a potential “functional cure” for Type 1 diabetes patients.

Tease photo